EU Sunscreens Are OTC Drugs in the USA: The FDA Compliance Gap European Exporters Miss

Plenty of European personal care brands have learned this the hard way. A sunscreen that sailed through EU Cosmetics Regulation (EC) No 1223/2009 compliance — CPNP notification done, safety assessment signed, Responsible Person appointed — gets stopped at the US border, or worse, flagged during a post-market FDA inspection. The brand’s regulatory team is baffled. Everything was correct. Every box was ticked.

The problem is that they ticked the wrong country’s boxes.

Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), sunscreens are classified as Over-the-Counter (OTC) drugs. Not cosmetics. That single regulatory classification changes almost everything: the permitted active ingredients, the manufacturing standard, the labeling format, the facility registration obligations, and the severity of the consequences when something goes wrong.

Why Sunscreens Land in a Different Regulatory Category in the US

FDA’s logic follows the product’s intended physiological effect. A sunscreen doesn’t merely improve appearance — it makes a drug claim. It prevents sunburn and, for products with SPF 15 or higher, may reduce the risk of skin cancer and early skin aging. Under 21 CFR §201.66 and FDA’s longstanding interpretation of the FD&C Act, any product that makes such a physiological claim is a drug, regardless of what its home market calls it.

The current US framework is governed by the OTC Monograph System, fundamentally reformed in March 2020 under Section 3851 of the CARES Act. The operative instrument for sunscreens is OTC Monograph M020, which replaced the proposed rules previously housed in 21 CFR Part 352. This is a binding administrative order with the force of federal regulation. It establishes which active ingredients are permitted, at what concentrations, in which formulation categories. And it applies to every sunscreen unit entering US commerce — imported or domestic.

What that means in practice: your product’s formulation, labeling, manufacturing documentation, and facility registration status must all conform to the monograph before a single shipment. There’s no discovery period, no “we’ll sort it out once we’re in the market” window.

The UV Filter Problem: Your EU-Approved Actives May Not Qualify

This is where most European brands encounter the first concrete, expensive obstacle. EU Annex VI under Regulation (EC) No 1223/2009 currently lists more than 30 approved UV filters for cosmetic use. FDA’s OTC sunscreen monograph permits exactly 16 active ingredients — and several of the most technically advanced modern filters used in European formulations simply don’t appear on that list.

Some examples that arise repeatedly when we review incoming European product dossiers:

• Bemotrizinol (Tinosorb S): broad-spectrum UVA/UVB coverage, widely used across EU-market SPF products — not FDA-approved for the US market
• Bisoctrizole (Tinosorb M): similarly standard in European formulations — not permitted under Monograph M020
• Drometrizole Trisiloxane (Mexoryl XL): popular for photostability — not approved
• Ecamsule (Mexoryl SX): partially permitted only in rinse-off face products at up to 3%, via a specific New Drug Application, not via the monograph

The Sunscreen Innovation Act of 2014 (Public Law 113-195) created a “Time and Extent Application” (TEA) pathway designed to allow established non-US UV filters to work through FDA review. Nearly a dozen TEA submissions have been filed over the past decade. As of mid-2026, FDA has approved none of them — a regulatory standstill that has frustrated the global industry and left European formulators with few good options.

The practical consequence is unambiguous: if your EU product’s SPF performance depends on Tinosorb S, Tinosorb M, or Mexoryl XL, you don’t have a US-compliant product. You have a reformulation project. And that reformulation typically costs more time and money than brands anticipate when they first map out a US launch.

What the OTC Monograph Actually Demands From Your Formulation and Label

Beyond the active ingredient list, Monograph M020 sets requirements that reach into every part of the product dossier.

Concentration ceilings. Avobenzone is one of the relatively few UV filters accepted in both EU and US markets. In the EU, it’s permitted at up to 5% under Annex VI. Under the FDA monograph, the ceiling is 3%. A formulation built at 4% avobenzone is legal in France and illegal in a US sunscreen — even though the ingredient appears on both permitted lists. That kind of detail is easy to miss and hard to fix after the label is printed.

Drug Facts labeling. EU sunscreen labels follow the cosmetics labelling directive — INCI nomenclature, function-based claims, net weight, country of origin. US OTC drug labels must carry a “Drug Facts” panel formatted precisely as specified in 21 CFR §201.66: active ingredients listed separately with their concentrations, purpose, directions, a “Skin Cancer/Skin Aging Alert” for products below SPF 15, warnings, and inactive ingredients in descending order of predominance. None of this maps neatly onto a CE-market label. A European design agency that has never worked on OTC drug labelling will produce something that requires a full restart.

SPF testing methodology. Both markets require SPF substantiation, but they use different protocols. The EU standard is ISO 24444:2010 (in vivo) alongside the COLIPA in vitro method. FDA expects testing aligned with its own established protocol, now carried forward under Monograph M020. In our experience coordinating transatlantic SPF testing, it’s not unusual to see a product rate SPF 50 under the EU method and SPF 45 under the US protocol. That gap can affect product positioning for brands built around a specific SPF tier, and it means your EU test reports cannot simply be submitted to FDA as-is.

cGMP Requirements: ISO 22716 Alone Won’t Satisfy an FDA Inspector

European cosmetics manufacturers are typically certified to ISO 22716, the GMP standard for cosmetics referenced under EU Regulation 1223/2009. That certification reflects genuine manufacturing quality. But for a product classified as an OTC drug in the US, ISO 22716 is not the applicable standard.

OTC drug manufacturers — including those manufacturing under contract for brand owners — must comply with 21 CFR Part 211, FDA’s Current Good Manufacturing Practice regulations for finished pharmaceuticals. The differences are substantial and, in an inspection, immediately visible:

Batch records. Part 211 requires master production and control records of a specificity that goes well beyond what ISO 22716 typically generates. Every input, every processing step, every in-process check is documented and traceable to raw data.

Laboratory controls. 21 CFR §211.68 and §211.194 require analytical records that include original raw data, complete instrument calibration histories, and full out-of-specification (OOS) investigation protocols with documented root cause analysis and disposition decisions.

Reserve samples. Finished product samples must be retained for at least 1 year past the product’s expiration date, or 3 years after the batch is distributed — whichever is longer. This requirement surprises cosmetics-trained QA managers who are accustomed to shorter retention obligations.

An FDA Establishment Inspection of a cosmetics-GMP facility manufacturing sunscreens will look for pharmaceutical-grade documentation. The gaps reliably generate Form 483 observations. In recurring or systemic cases, they escalate to Warning Letters — which become public record and complicate every subsequent regulatory interaction.

Registration Steps That Must Happen Before Your First US Shipment

Two federal registration obligations apply before a single unit of sunscreen legally enters US commerce. Neither exists in the EU cosmetics framework, and both require more lead time than brands typically plan for.

Drug Establishment Registration (21 CFR Part 207). The facility where your sunscreen is manufactured — your own plant or a contract manufacturer’s — must be registered with FDA as a drug establishment. Foreign facilities must register annually during the June registration window and must appoint a US Agent who can receive official FDA correspondence. A contract manufacturer that is registered for cosmetics production only is not registered for OTC drug manufacturing. That distinction matters, and resolving it takes time.

Drug Listing and National Drug Code (NDC). Each distinct sunscreen SKU must be listed in FDA’s National Drug Code directory. The listing includes active ingredients, concentration, dosage form, labeling, and an SPL-formatted (Structured Product Labeling) copy of the Drug Facts panel. Unlisted OTC drug products are illegal to market in the US. Full stop.

Both steps are completed through FDA’s Electronic Submissions Gateway using SPL format. If your regulatory affairs team hasn’t navigated SPL submissions before, budget time for the learning curve — the format is specific and unforgiving of structural errors.

Building a Realistic US Market Entry Timeline

The compliance gap between an EU-ready sunscreen and a US-ready OTC drug is real, and closing it takes time. Based on projects we’ve supported for European personal care brands, a realistic timeline looks like this:

• Formulation review and active ingredient assessment: 2–4 weeks to identify gaps; 3–6 months if reformulation is required
• SPF re-testing under FDA protocol: 6–10 weeks per test series, depending on lab scheduling
• Drug Facts label design and regulatory review: 4–6 weeks
• Facility cGMP gap assessment and remediation: highly variable; typically 2–6 months for a cosmetics GMP plant
• FDA Establishment Registration and Drug Listing: 2–4 weeks once SPL documents are correctly prepared

A brand with a fully EU-compliant formulation that needs no reformulation — using only avobenzone, zinc oxide, titanium dioxide, or another FDA-monograph active at compliant concentrations — might realistically reach first legal shipment in 6–8 months. A brand that discovers its hero actives aren’t FDA-permitted is looking at 12–18 months minimum.

The same cross-classification trap applies to other product categories European brands frequently underestimate: anti-dandruff shampoos containing zinc pyrithione or selenium sulfide, fluoride toothpastes, acne treatments formulated with benzoyl peroxide or salicylic acid, and antiperspirants containing aluminum-based actives. All are OTC drugs in the US. A brand that ships them as cosmetics is shipping illegal drugs — regardless of how they’re classified on the other side of the Atlantic.

Start Here: A Product Classification Audit Before Anything Else

If your brand has US export ambitions, or if you’re already shipping products to the US without having formally evaluated their FDA regulatory classification, the right first step isn’t a reformulation project or an NDA filing. It’s a classification audit of your full range — a structured review of each SKU against FDA’s OTC drug category definitions, your label claims, and your active ingredient list.

That audit produces a clear categorisation: which products are cosmetics in the US, which are OTC drugs, and which sit in a grey zone depending on how marketing claims are worded. It changes the nature of every subsequent conversation — with your contract manufacturer about facility registration, with your testing partner about SPF methodology, with your regulatory counsel about timelines and realistic budget. It’s the document that tells you what kind of problem you actually have, before you’ve spent significant budget on the wrong solution.

European brands that approach the US market assuming product category equivalence between EU and US regulations don’t fail because they didn’t care about compliance. They fail because nobody told them the starting point was wrong.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry Contact us

Related from our network

• ISO 17025-Accredited SPF Testing and OTC Drug Analytics for the US Market — Qalitex Laboratories supports European brands with FDA-protocol SPF testing, cGMP documentation review, and OTC drug compliance for US market entry.
• Health Canada OTC Drug Classification for European Personal Care Brands — Androxa guides European cosmetics and supplement brands through Health Canada’s NHP and OTC drug classification process for Canadian market entry.